Names and pronunciation
(broe-lue-siz′-ue-mab-dbll) Beovu
PDF page 194
Loading InternPractice…
Drug reference
(broe-lue-siz′-ue-mab-dbll) Beovu
PDF page 194
Func. class.: Ophthalmic agent
PDF page 194
Chem. class.: VEGF inhibitor
PDF page 194
ACTION: Binds to VEGF, suppresses endothelial cell proliferation, neovascularization, and vascular permeability
PDF page 194
USES: Neovascular (wet) age-related macular degeneration
PDF page 194
CONTRAINDICATIONS Ocular/periocular infections, active intra- ocular inflammation, hypersensitivity Precautions: Endophthalmitis, retinal detachment, retinal vasculitis and/or reti- nal vascular occlusion, increased IOP, arterial thromboembolic events
PDF page 194
SIDE EFFECTS EENT: Blurred vision, cataract, conjunc- tival hemorrhage, eye pain, floaters
PDF pages 194, 195
INTERACTIONS None known
PDF page 195
DOSAGE AND ROUTES • Adult: Intravitreal injection 6 mg (0.05 mL of 120 mg/mL solution) monthly × 3 doses, then 6 mg (0.05 mL) q8-12wk
PDF page 194
Available forms: Intravitreal injection: 6 mg/0.05 mL solution single-dose vial
PDF page 194
Administer: • Given by ophthalmologist • Inspect solution for discoloration or particulate matter, do not use if present • Vial is for single use, discard unused portion • Refrigerate vial, do not freeze. Store the vial in the outer carton to protect from light; before use, the unopened glass vial may be kept at room temperature for ≤24 hr
PDF page 194
Assess: • Monitor IOP for 30 min after injection • Assess for arterial thromboembolic events after injection • Pregnancy/breastfeeding: Not to use in pregnancy, use contraception if woman is of childbearing potential; not to breast- feed during or for 1 mo after conclusion of treatment
PDF page 195
Evaluate: • Therapeutic response: Prevention of loss of sight
PDF page 195
CLINICAL CONSIDERATIONS
PDF page 195
Patient and caregiver information: • Inform patients that after injection en- dophthalmitis, retinal detachment, retinal vasculitis, retinal vascular occlusion may occur; if the eye becomes red, sensitive to light, painful, or change in vision occurs, immediately contact ophthalmologist • Teach patients that temporary visual disturbances may occur after injection • Advise patients not to drive or use machinery until reaction is known
PDF page 195
PHARMACOKINETICS Onset, duration unknown, peak 24 hr, half-life 4.4 days
PDF page 195
• Adult: Intravitreal injection 6 mg (0.05 mL of 120 mg/mL solution) monthly × 3 doses, then 6 mg (0.05 mL) q8-12wk
PDF page 194